CXCR4 and infection: CB2 agonist have been shown to decrease CXCR4-activation-mediated G-protein activity and MAPK phosphorylation, alter the cytoskeletal architecture of resting CD4+ T and impair productive infection following cell-free or cell-associated viral acquisition of CXCR4-tropic HIV-1 in resting cells.